Mirae Asset Capital Life Science is a venture capital firm established in 2023, specializing in providing financial solutions for companies focused on life sciences. With investment professionals based in Boston and San Francisco, the firm targets therapeutics companies at various stages of development, from seed funding to Series C rounds. Mirae Asset Capital Life Science aims to support innovative companies that prioritize advancements in life science, contributing to the growth and evolution of the industry.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Accent Therapeutics
Series C in 2024
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.